The Lancet Oncology in conversation with cover art

The Lancet Oncology in conversation with

The Lancet Oncology in conversation with

By: The Lancet Group
Listen for free

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.© 2026 The Lancet Group Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission

    Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
    May 31 2026

    Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission.

    To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce.

    To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3
    Show More Show Less
    24 mins
  • Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

    Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
    Apr 27 2026

    Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.

    Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext
    Show More Show Less
    13 mins
  • James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

    James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
    Mar 30 2026

    Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

    Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext

    Tell us what you thought about this episode

    Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

    You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

    Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
    Show More Show Less
    11 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet